| 0.8225 0 (0%) | 04-28 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
IMV Inc., a clinical-stage biotechnology company founded in 2000 and based in Dartmouth, Canada, is focused on immuno-oncology. The firm develops a range of therapeutic candidates for solid and hematological cancers utilizing its proprietary DPX immune-educating technology platform. Its primary drug candidate, maveropepimut-S, is a DPX-based immunotherapy engineered to specifically target survivin-expressing cells. This compound is currently in Phase II clinical trials for several cancer types, including diffuse large B cell lymphoma, ovarian cancer, bladder cancer, liver cancer, and tumors exhibiting high microsatellite instability. Maveropepimut-S is also being investigated in a Phase I clinical trial for breast cancer. The company's pipeline further includes DPX-SurMAGE, which is in Phase I development for bladder cancer, as well as DPX-COVID-19 and DPX-RSV, both aimed at addressing infectious diseases. IMV Inc. was previously known as Immunovaccine Inc. before changing its name in May 2018.
Mon, 01 Jun 2026
Number of shareholders of IMV Corporation – TSE:7760 - TradingView
Thu, 15 Feb 2024
BioVaxys Acquires Full Portfolio of Former IMV - PharmTech.com
Tue, 13 Feb 2024
BioVaxys snatches up ‘bankrupt’ IMV’s preclinical and clinical assets - Pharmaceutical Technology
Mon, 12 Feb 2024
BioVaxys Acquires IP, Immunotherapeutics Platform Technology & Assets of IMV Inc. - Contract Pharma
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|